Achillion Pharmaceuticals, Inc.  

(Public, NASDAQ:ACHN)   Watch this stock  
Find more results for ACHN
11.75
+0.97 (9.00%)
After Hours: 11.78 +0.03 (0.26%)
Aug 26, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.90 - 12.06
52 week 2.26 - 12.06
Open 11.22
Vol / Avg. 0.00/4.65M
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -0.61
Shares 97.79M
Beta 2.00
Inst. own 100%
Nov 10, 2014
Q3 2014 Achillion Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 7, 2014
Q2 2014 Achillion Pharmaceuticals Inc. Earnings Release
Jun 24, 2014
Achillion Pharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 18, 2014
Achillion Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Jun 3, 2014
Achillion Pharmaceuticals Inc. 2014 Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -44.36% -48.33%
Return on average equity -47.50% -52.40%
Employees 61 -
CDP Score - -

Address

300 George Street
NEW HAVEN, CT 06511
United States - Map
+1-203-6247000 (Phone)
+1-203-6247003 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The Company is engaged in the development of antivirals for the treatment of chronic hepatitis C infection (HCV), and the development of antibacterials for the treatment of resistant bacterial infections. The Company focuses on the development of four drug candidates for the treatment of HCV: ACH-1625, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase IIa clinical trial, ACH-2684, a NS3 protease inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial; ACH-2928, a NS5A inhibitor for the treatment of HCV, which is being tested in a phase I clinical trial, and ACH-3102, a NS5A inhibitor for the treatment of HCV, which is being prepared for investigational new drug (IND), filing and initiation of a phase I clinical trial.

Officers and directors

David I. Scheer Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Milind S. Deshpande Ph.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Mary Kay Kay Fenton CPA Chief Financial Officer, Senior Vice President
Age: 50
Bio & Compensation  - Reuters
Gautam Shah Ph.D. Executive Vice President, Chief Compliance Officer
Age: 57
Bio & Compensation  - Reuters
David Apelian M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Joseph Truitt Senior Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Michael D. Kishbauch Director
Age: 65
Bio & Compensation  - Reuters
Jason S. Fisherman M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Gary E. Frashier Independent Director
Age: 75
Bio & Compensation  - Reuters
Kurt C. Graves Independent Director
Age: 46
Bio & Compensation  - Reuters